- Home
- CRNX vs XNDU Comparison
CRNX vs XNDU Comparison
Compare CRNX & XNDU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRNX | XNDU |
|---|---|---|
| Founded | 2008 | 2016 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.5B |
| IPO Year | 2018 | 2025 |
Fundamental Metrics
Financial Performance| Metric | CRNX | XNDU |
|---|---|---|
| Price | $84.97 | $9.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 2 |
| Target Price | ★ $76.75 | $44.00 |
| AVG Volume (30 Days) | ★ 2.4M | 1.2M |
| Earning Date | 05-07-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,039,000.00 | N/A |
| Revenue This Year | $720.10 | N/A |
| Revenue Next Year | $184.67 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $32.30 | $6.97 |
| 52 Week High | $85.01 | $42.44 |
Technical Indicators
Market Signals| Indicator | CRNX | XNDU |
|---|---|---|
| Relative Strength Index (RSI) | 89.88 | 44.14 |
| Support Level | $83.47 | $9.70 |
| Resistance Level | N/A | $11.64 |
| Average True Range (ATR) | 0.12 | 0.53 |
| MACD | -0.86 | -0.04 |
| Stochastic Oscillator | 93.85 | 26.81 |
Price Performance
Historical ComparisonAbout CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
About XNDU Xanadu Quantum Technologies Limited Class B Subordinate Voting Shares
Xanadu Quantum Technologies Ltd specializes in designing photonic devices and the platforms around them, including the experimentation and development of quantum computers available on the cloud with supporting software, along with quantum simulators and other related products and offerings. Its products include: Aurora, PennyLane, Catalyst, Lightning, Catalyst and PennyLane Codebook. The company operates in industries such as automotive, aerospace, energy, materials, and semiconductor sectors.